Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy

The STAR 3 experience

John B. Buse, George Dailey, Andrew Ahmann, Richard M. Bergenstal, Jennifer B. Green, Tim Peoples, Robert J. Tanenberg, Qingqing Yang

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit). Methods: Baseline characteristics were compared with A1C benefit. Statistically significant predictors were analyzed further to determine appropriate cutpoints of relative A1C benefit. Results: Baseline A1C ≥9.1%, age at randomization ≥36 years, and age at diabetes diagnosis of ≥17 years were associated with a greater SAP benefit relative to MDI than other cutpoints. Conclusions: People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at randomization experienced the most benefit from SAP therapy.

Original languageEnglish (US)
Pages (from-to)601-606
Number of pages6
JournalDiabetes Technology and Therapeutics
Volume13
Issue number6
DOIs
StatePublished - Jun 1 2011

Fingerprint

Random Allocation
Injections
Type 1 Diabetes Mellitus
Hypoglycemia
Therapeutics
Randomized Controlled Trials
Incidence

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medical Laboratory Technology

Cite this

Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy : The STAR 3 experience. / Buse, John B.; Dailey, George; Ahmann, Andrew; Bergenstal, Richard M.; Green, Jennifer B.; Peoples, Tim; Tanenberg, Robert J.; Yang, Qingqing.

In: Diabetes Technology and Therapeutics, Vol. 13, No. 6, 01.06.2011, p. 601-606.

Research output: Contribution to journalArticle

Buse, John B. ; Dailey, George ; Ahmann, Andrew ; Bergenstal, Richard M. ; Green, Jennifer B. ; Peoples, Tim ; Tanenberg, Robert J. ; Yang, Qingqing. / Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy : The STAR 3 experience. In: Diabetes Technology and Therapeutics. 2011 ; Vol. 13, No. 6. pp. 601-606.
@article{c0c18034abe040cfa8775a4b2a83db36,
title = "Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: The STAR 3 experience",
abstract = "Background: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5{\%} A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit). Methods: Baseline characteristics were compared with A1C benefit. Statistically significant predictors were analyzed further to determine appropriate cutpoints of relative A1C benefit. Results: Baseline A1C ≥9.1{\%}, age at randomization ≥36 years, and age at diabetes diagnosis of ≥17 years were associated with a greater SAP benefit relative to MDI than other cutpoints. Conclusions: People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at randomization experienced the most benefit from SAP therapy.",
author = "Buse, {John B.} and George Dailey and Andrew Ahmann and Bergenstal, {Richard M.} and Green, {Jennifer B.} and Tim Peoples and Tanenberg, {Robert J.} and Qingqing Yang",
year = "2011",
month = "6",
day = "1",
doi = "10.1089/dia.2010.0225",
language = "English (US)",
volume = "13",
pages = "601--606",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy

T2 - The STAR 3 experience

AU - Buse, John B.

AU - Dailey, George

AU - Ahmann, Andrew

AU - Bergenstal, Richard M.

AU - Green, Jennifer B.

AU - Peoples, Tim

AU - Tanenberg, Robert J.

AU - Yang, Qingqing

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit). Methods: Baseline characteristics were compared with A1C benefit. Statistically significant predictors were analyzed further to determine appropriate cutpoints of relative A1C benefit. Results: Baseline A1C ≥9.1%, age at randomization ≥36 years, and age at diabetes diagnosis of ≥17 years were associated with a greater SAP benefit relative to MDI than other cutpoints. Conclusions: People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at randomization experienced the most benefit from SAP therapy.

AB - Background: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit). Methods: Baseline characteristics were compared with A1C benefit. Statistically significant predictors were analyzed further to determine appropriate cutpoints of relative A1C benefit. Results: Baseline A1C ≥9.1%, age at randomization ≥36 years, and age at diabetes diagnosis of ≥17 years were associated with a greater SAP benefit relative to MDI than other cutpoints. Conclusions: People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at randomization experienced the most benefit from SAP therapy.

UR - http://www.scopus.com/inward/record.url?scp=79957598950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957598950&partnerID=8YFLogxK

U2 - 10.1089/dia.2010.0225

DO - 10.1089/dia.2010.0225

M3 - Article

VL - 13

SP - 601

EP - 606

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

IS - 6

ER -